Source comparison
Best CJC-1295 Dosage for Growth Hormone Release: Clinical vs Research Protocols Comparison
Clinical (GH Deficiency) 60 mcg/kg (≈4200 mcg for 70 kg) Once weekly Normalize IGF-1 in deficient populations Moderate. Monitored via IGF-1 bloodwork Effective for pathological deficiency but exceeds saturation threshold in healthy individuals Research (Perfor
This comparison does not assign a generated winner or score.
- Clinical (GH Deficiency)
- 60 mcg/kg (≈4200 mcg for 70 kg)
- Once weekly
- Normalize IGF-1 in deficient populations
- Moderate. Monitored via IGF-1 bloodwork
- Effective for pathological deficiency but exceeds saturation threshold in healthy individuals
- Research (Performance)
- 1000–1500 mcg
- Amplify endogenous GH pulses without supraphysiological IGF-1
- Low. Remains below pituitary saturation in most users
- Optimal balance of efficacy and safety for non-deficient populations
- Research (Aggressive)
- 2000–2500 mcg
- Twice weekly
- Maximize anabolic signaling and lipolysis
- High. Frequently exceeds receptor capacity without additional benefit
- Produces measurable IGF-1 elevation but marginal GH pulse improvement over 1500 mcg weekly
- Maintenance (Post-Cycle)
- 500–1000 mcg
- Every 10–14 days
- Sustain mild GH elevation during washout periods
- Minimal. Well below saturation threshold
- Extends benefits between full cycles without inducing receptor desensitization
- The comparison underscores a critical point: clinical doses designed to correct pathological GH deficiency are not optimized for healthy individuals seeking performance or body composition benefits. The therapeutic window is narrower than most protocols acknowledge.